Monash Partners Comprehensive Cancer Consortium awards precision medicine grants

Latest News

Monash Partners Comprehensive Cancer Consortium (MPCCC) has announced the recipients of the Precision Treatment Accelerator Grant.

MPCCC is a network of hospitals and universities working to advance cancer care through research.

The grant supports research that advances precision cancer treatment. Four projects have been awarded a total of $426,184.

“We are excited to support these four projects,” said MPCCC co-director Professor Mark Shackleton.

“They will build capacity for the application of high-quality precision cancer care that will be easily integrated into our busy Molecular Tumour Board program, supporting even more patients and clinicians to access the therapies and clinical trials they need, thereby addressing the MPCCC's strategic priorities. Congratulations to the successful applicants.”

The four projects are focused on early detection of high-risk multiple myeloma, liquid biopsy using blood and exhaled breath condensate analysis of circulating tumour DNA in advanced non-small cell lung cancer, a precision oncology platform for brain tumours, and the integration of an MPCCC fellow within the Aboriginal and Torres Strait Islander Oncology Service at Eastern Health to improve access to precision cancer program and trials.